Anti-OX40 antibody and application thereof
The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.
1. An anti-OX40 antibody or an antigen-binding part thereof, comprising a group of CDRs selected from the following groups:
1) a heavy chain variable region CDR1, CDR2 and CDR3 having a sequence as set forth in SEQ ID NO: 5-7 respectively, a light chain variable region CDR1, CDR2 and CDR3 having a sequence as set forth in SEQ ID NO: 14-16 respectively;
2) a heavy chain variable region CDR1, CDR2 and CDR3 having a sequence as set forth in SEQ ID NO: 23-25 respectively, a light chain variable region CDR1, CDR2 and CDR3 having a sequence as set forth in SEQ ID NO: 32-34 respectively;
3) a heavy chain variable region CDR1, CDR2 and CDR3 having a sequence as set forth in SEQ ID NO: 41-43 respectively, a light chain variable region CDR1, CDR2 and CDR3 having a sequence as set forth in SEQ ID NO: 50-52 respectively;
4) a heavy chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 63, 42, 43 respectively, a light chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 50-52 respectively;
5) a heavy chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 41, 67, 43 respectively, a light chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 50-52 respectively;
6) a heavy chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 41, 42, 70 respectively, a light chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 50-52 respectively;
7) a heavy chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 63, 67, 70 respectively, a light chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 75-77 respectively, and
8) a heavy chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 41, 42, 70 respectively, a light chain variable region CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 75-77 respectively.
2. The anti-OX40 antibody or the antigen-binding part thereof according to, claim 1 , comprising a heavy chain variable region having a sequence selected from the group consisting of SEQ ID NO: 4, 22, 40, 62, 66, 69, 72 and 79.
3. The anti-OX40 antibody or the antigen-binding part thereof according to, claim 1 , comprising a light chain variable region having a sequence selected from the group consisting of SEQ ID NO: 13, 31, 49 and 74.
4. A conjugate, comprising the anti-OX40 antibody or the antigen-binding part thereof according to claim 1 , and an additional bioactive substance, wherein the anti-OX40 antibody or the antigen-binding part thereof is conjugated, either directly or through a linker, to the additional bioactive substance.
5. A composition, comprising the anti-OX40 antibody or antigen-binding part thereof according to claim 1 , and optionally a pharmaceutically acceptable carrier or excipient.
6. A method for treating a tumor in a subject, comprising administering to said subject a therapeutically effective amount of the anti-OX40 antibody or the antigen-binding part thereof according to claim 1 .